Tazerestat (Taveco) dosage, usage and daily medication instructions
Tazemetostat (Tazemetostat, trade name: Tazverik) is an oral small molecule selectiveEZH2inhibitors are mainly used to treat specific tumors such as relapsed or refractory peripheral TT cell lymphoma (PTCL) and epithelioid sarcoma. The drug inhibits EZH2 enzyme activity and blocks histone methylation modification, thereby affecting the proliferation and differentiation of tumor cells and achieving anti-tumor effects.
The recommended dose for adult patients is 800mg taken orally twice daily with or without food. Tablets should be swallowed whole and not crushed or chewed to ensure drug absorption and efficacy. It is recommended that the interval between two daily doses should be as even as possible, preferably about 12 hours, to ensure stable blood concentration.

During treatment, patients may experience side effects such as abnormal liver function, hematological adverse reactions, or severe fatigue. For patients with mild liver function impairment, the regular dose can be maintained, but liver function needs to be monitored regularly; for patients with moderate to severe liver function impairment, doctors may need to reduce the dose or extend the dosing interval. At the same time, blood routine and liver function should be checked regularly before and during treatment so that the dosage can be adjusted in time.
Patients should take the medicine at a fixed time and try to take it at the same time every day to ensure the efficacy. If you miss a dose, you should take it as soon as possible. However, if it is close to the time of the next dose, skip the missed dose and do not double the dose. During the period of taking the medicine, you should avoid using it at the same time with drugs that may affect liver enzyme metabolism, and pay attention to observe adverse reactions. If there is severe liver function damage, a significant decrease in platelets, etc., you should seek medical treatment immediately. Correct use of tazerestat can reduce the risk of adverse reactions while ensuring efficacy.
Reference materials:https://www.drugs.com/
xa0
[ 免责声明 ] 本页面内容来自公开渠道(如FDA官网、Drugs官网、原研药厂官网等),仅供持有医疗专业资质的人员用于医学药学研究参考,不构成任何治疗建议或药品推荐。所涉药品可能未在中国大陆获批上市,不适用于中国境内销售和使用。如需治疗,请咨询正规医疗机构。本站不提供药品销售或代购服务。
.jpeg)